No business profile yet.
Size Center Laboratories (4123.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $639M, the 354th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$27.10 on 18 Nov 2026.
Performance Over six months the shares fell 29.3%, against -18.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 13.6% over the last twelve months (peer median +8.6%); the operating margin is 9.2% (peer median 7.9%).
Valuation It trades at 12.8× enterprise value to sales against a peer median of 3.2× (3rd most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.3 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$1.78B | NT$1.52B | NT$1.62B | NT$1.39B | NT$768M |
| Revenue growth | — | -6% | +16% | +82% | — |
| Gross profit | NT$726M | NT$552M | NT$678M | NT$618M | NT$393M |
| EBITDA | NT$346M | NT$257M | NT$391M | NT$221M | NT$99.6M |
| Net income | -NT$1.69B | NT$9.32B | -NT$1.10B | -NT$995M | NT$102M |
| Free cash flow | NT$289M | -NT$21.1M | NT$317M | -NT$774M | NT$226M |
| Capital expenditure | NT$147M | NT$208M | NT$178M | NT$172M | NT$8.43M |
| Total debt | NT$4.16B | NT$4.70B | NT$6.53B | NT$5.62B | NT$3.47B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4123.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.6% | -9.1% | 5th lowest of 20 |
| 6-month return | -29.3% | -18.1% | 7th lowest of 20 |
| Distance from 52-week high | -47.3% | -36.4% | 8th lowest of 20 |
| Revenue growth (TTM) | +13.6% | +8.6% | 6th highest of 17 |
| Operating margin | 9.2% | 7.9% | 8th highest of 16 |
| EV / Sales | 12.8× | 3.2× | 3rd most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 36.3% | 9.6% | most demanding of 11 |
| Growth delivered (Del g) | +16.2% | +6.6% | 3rd highest of 11 |
| Hurdle (Req g minus delivered) | +20.1 pp | +10.1 pp | 2nd most demanding of 11 |
| ROIC minus cost of capital | -4.3 pp | -3.4 pp | 6th lowest of 14 |
| EV / EBITDA | 66.0× | 8.2× | most expensive of 7 |
| Net debt / EBITDA | 5.2× | -0.4× | 2nd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | 12.8× | 36.3% | +16.2% |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 3.0× | 9.1% | +7.9% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | 10.6× | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 3.4× | 27.1% | +31.4% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | 16.9× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | 1.6× | n/a | n/a |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | 2.4× | 25.2% | +10.3% |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | 5.3× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | 2.5× | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 3.0× | -8.7% | +8.8% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 6.1× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | 2.4× | 10.9% | -5.9% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | 3.3× | 10.1% | +2.1% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 25.1× | 9.1% | -25.1% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | 2.0× | -1.0% | -17.9% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 0.5× | -6.6% | +5.4% |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 6.7× | 31.9% | +19.8% |